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iabetes induces a high degree of
morbidityandsigniﬁcantreduction
of life expectancy in affected sub-
jects. Microvascular complications in-
clude retinopathy, nephropathy, and
neuropathy, which frequently are under-
lying factors of major morbidity and dis-
abilityassociatedwithdiabetes.However,
macrovascularcomplications,andmainly
cardiovascular disease, are still the lead-
ing causes of death in diabetic subjects.
Thus, improved cardiovascular outcome
willhaveaclearlyfavorableeffectonmor-
tality in this group of patients.
Since the introduction of the U.K.
Prospective Diabetes Study (UKPDS) tri-
als in 1998, it has become widely ac-
cepted that controlling hyperglycemia
improves microvascular outcome in dia-
betic patients (1,2). However, to date,
there is no compelling evidence that im-
proving glycemic control has, in itself,
beneﬁcial effects on macrovascular com-
plications and cardiovascular clinical end
points.
Although hyperglycemia is the hall-
markofdiabetes,itisstillunclearwhether
there is a causative relationship between
increased blood glucose levels and the
evolution of arterial atherosclerosis.
Moreover, other metabolic disorders that
have been clearly linked to plaque forma-
tion seem to coexist with, rather than be-
ing caused by, hyperglycemia. These
metabolic abnormalities include dyslipi-
demia, abdominal obesity, hypertension,
low-grade inﬂammation, and coagulopa-
thies. This hypothesis is supported by the
ﬁndings of Haffner et al. (3) from a pop-
ulation-based study of diabetes and car-
diovascular disease. In this study, it was
demonstrated that normoglycemic sub-
jects who subsequently developed diabe-
tes had an atherogenic pattern of risk
factors, including dyslipidemia, over-
weight, insulin resistance, and hyperten-
sion, years before frank diabetes was
diagnosed (3). In another study, Haffner
et al. (4) clearly demonstrated that dia-
betic patients without previous myocar-
dial infarction (MI) have as high a risk of
MI as nondiabetic patients with previous
MI. Overall, these ﬁndings support the
hypothesisthatdiabetesandotherathero-
genic risk factors are manifestations of
oneentityleadingtoarterialatherosclero-
sis. The constellation of insulin resistance
and abnormal glucose metabolism with
other atherogenic risk factors is com-
monly referred to as the metabolic
syndrome.
DIABETES, ENDOTHELIAL
DYSFUNCTION, AND
SYSTEMIC INFLAMMATION
IN CARDIOVASCULAR
DISEASE— Endothelial dysfunction
is a characteristic feature of atherosclero-
sis, and studies indicate that it may pre-
dict long-term disease progression, as
well as the rates of cardiovascular events.
The endothelial system is the largest en-
docrineorganinprimates,whereitserves
as an internal nonclotting lining of blood
vessels by producing a number of antico-
agulant factors including nitric oxide,
prostacyclin, tissue plasminogen activa-
tor, protein C, and protein S. It also func-
tions as a semi-permeable membrane for
macromolecules in the bloodstream. The
endothelium regulates vascular smooth
muscle tone through the release of sub-
stances such as nitric oxide (NO), prosta-
cyclin, and endothelin. It also plays a key
role in platelet adhesion and aggregation
by secreting a number of prothrombotic
agents including von Willebrand factor,
plasminogen activator inhibitor, and tis-
sue factor (5).
Dysfunctionoftheendothelialsystem
involvesdisruptionofbarrierintegrity,al-
lowing LDL molecules leakage into the
vessel wall. Diseased endothelial cells ex-
press molecules that allow leukocyte
binding and penetration into the sub-
endothelial space. Leukocytes, mainly T-
cells, together with endothelial cells
produce and release various cytokines
that attract monocytes driven to differen-
tiate into phagocytes. Within the vessel
wall, LDL molecules are rapidly oxidized
and engulfed by phagocytes to form foam
cells.EnhancedLDLoxidationindiabetic
subjectsisattributedtoincreasedproduc-
tion of reactive oxygen species and an im-
paired scavenging system. Accumulation
of foam cells attracts other inﬂammatory
cellsandﬁbroblaststhatproducecollagen
ﬁbers and create the ﬁbrous cap sur-
rounding the lipid core. Local cytokines
and macrophage-derived matrix metallo-
proteinases partially degrade the ﬁbrous
cap, rendering it prone to rupture. Con-
tact between the blood and the proco-
agulant lipid core initiates thrombus
formation and vessel occlusion. The local
inﬂammatory response is accompanied
by generalized inﬂammation that is re-
ﬂected by increased plasma levels of in-
terleukin (IL)-1, IL-6, C-reactive protein,
tumor necrosis factor- (TNF-), and
complement components. These inﬂam-
matorymoleculesarealsoincreasedinin-
sulin resistance, conﬁrming the
association between this entity and ath-
erosclerosis development and progres-
sion. Insulin resistance is also associated
with increased platelet activation and im-
paired ﬁbrinolytic activity (5).
Thus, a comprehensive approach and
management of all identiﬁed risk factors
is needed to improve cardiovascular out-
come in diabetes. Recently published
studies demonstrated that intensiﬁed
treatment of multiple risk factors in dia-
beticpatientsresultsinmarkedreduction
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mortality (6). Overall, an antidiabetic
agent will ideally address multiple risk
factors to prove beneﬁcial for the preven-
tion of atherosclerosis in diabetic sub-
jects. Until we have solid evidence of
improved cardiovascular clinical out-
comes related to tight glucose control, we
should be cautious when interpreting
ﬁndings that mainly demonstrate reduc-
tion of risk factors or surrogate markers.
That being said, correcting hyperglyce-
mia should be attempted to prevent mi-
crovascular complications and possibly
delayatherosclerosisprogressionandma-
crovascular complications.
ORAL HYPOGLYCEMIC
AGENTS AND
CARDIOVASCULAR
CLINICAL OUTCOME: IS
THERE EVIDENCE?— The uncer-
tainty that oral hypoglycemic agents
(OHAs) contribute to the prevention of
macrovascularcomplicationsaffectsdeci-
sion-making by physicians and patients
worldwide. This uncertainty is a direct
outcome of multiple factors: diversity of
drugs from different classes, a huge
amount of information that is largely de-
rived from industry-sponsored clinical
trials, and aggressive marketing. In a sys-
tematic review by Bolen et al. (7), 216
studies of OHAs were analyzed. They
concluded that the evidence of OHAs re-
ducing cardiovascular mortality is still in-
conclusive. Our current review describes
the status of evidence on the cardiovascu-
larriskfactorsandonclinicaloutcomefor
different OHAs.
Sulfonylureas
Sulfonylureas exert their activity through
induction of insulin release by pancreatic
-cells. Upon binding to sulfonylurea re-
ceptor 1 (SUR1) on the -cell membrane,
these agents induce closure of the adja-
cent potassium ATP-dependent (KATP)
channelleadingtomembranedepolariza-
tion. Subsequent opening of voltage-
gated calcium channels in the plasma
membraneleadstoincreasedintracellular
calcium concentrations and insulin re-
lease (8).
In addition to being potent hypogly-
cemic agents, the use of sulfonylureas is
accompaniedbyconsiderableweightgain
and worsening obesity, together with the
adverse consequences of this undesirable
side effect (8). Although some studies
demonstrated modest improvement in
thelipidproﬁle,thechangewithsulfonyl-
urea therapy did not reach statistical sig-
niﬁcance (9). In the study by Charbonnel
etal.(10),gliclazidemonotherapywasas-
sociated with a 5% reduction in LDL lev-
els and 14% in triglycerides over 52
weeks’ follow-up. When added to met-
formin therapy, gliclazide had a minor ef-
fect on LDL (3%) and triglyceride (7%)
levels(11).Theimprovedlipidproﬁleob-
served with gliclazide was modest com-
pared with pioglitazone therapy in the
latter two studies. This ﬁnding induced
the inevitable assumption that improved
lipid proﬁle was solely a reﬂection of bet-
ter glycemic control with gliclazide. It is
noteworthy that the effect of metiglinide
therapy on lipid proﬁle has been incon-
sistent among different studies.
There is no evidence that sulfonyl-
ureas have positive effects on blood pres-
sure. Nevertheless, a 52-week treatment
with glyburide was associated with a
small increase in systolic blood pressure
(12). Minor blood pressure reduction
(0.7 mmHg systolic and 0.6 mmHg dia-
stolic)wasassociatedwithgliclazidether-
apy (13). However, patients on gliclazide
hadanincreasedincidenceofnewlydiag-
nosed hypertension and exacerbation of
existing hypertension, compared with
metformin and pioglitazone therapy in
the same study.
Studies examining the effect of sulfo-
nylurea therapy on microalbuminuria re-
vealed conﬂicting results. Gliclazide
monotherapywasdemonstratedtoexerta
positiveeffectonmicroalbuminuriaindi-
abetic subjects (14). However, when
added to existing metformin therapy, gli-
clazide had no additional renoprotective
beneﬁt in one study (14) and even dele-
terious effects in another (11).
The effects of sulfonylureas on in-
ﬂammatory markers are conﬂicting, and
the studies examining these end points
are relatively small, raising questions
about their validity.
Concerns about increased cardiovas-
cularriskuponsulfonylureatherapyorig-
inate from physiologic and clinical data.
While SUR1 is expressed in -cells,
SUR2AandSUR2Bareexpressedincar-
diomyocytes and smooth muscle cells,
respectively. The KATP channel in cardio-
myocytes has an important function in its
adaptation to cardiac ischemia. In isch-
emic conditions, the KATP is kept open,
allowing muscle relaxation, vascular dila-
tation, and reduced oxygen demand. On
pharmacologicclosureofthechannel,the
cardiac adaptation mechanism is im-
paired, leading to increased muscle cell
necrosisandmoreextensivecardiacdam-
age in response to acute ischemia.
Namely, glibenclamide was shown to ex-
ert detrimental effects on cardiomyocyte
adaptation to ischemia in animal models.
A possible interaction between its benz-
amido moiety and the SUR2A in cardio-
myocytes constitutes the physiologic
explanation for possible adverse cardiac
eventsrelatedtoglibenclamide.However,
it was also demonstrated that gliben-
clamidewasassociatedwithreducedrates
of cardiac arrhythmias on ischemia in an-
imal models.
In1970,theUniversityGroupDiabe-
tes Program demonstrated a signiﬁcant
increaseincardiovascularmortalityinthe
tolbutamide-treated group compared
with placebo and insulin therapy (15).
The University Group Diabetes Program
results were extensively criticized due to
randomization errors, the inclusion of
nondiabetic patients, and poor compli-
ance. However, shortly thereafter, other
clinical trials were published showing the
same type of results: less survivors after
MI in diabetic patients treated with oral
antidiabetic therapy in comparison with
diet only, or insulin therapy (16). Al-
though recent studies made a distinction
between the older-generation sulfonyl-
ureas and the newer agents, the fear of
glibenclamide containing the benzamido
group still exists. Noteworthy, unlike
glibenclamide, tolbutamide lacks the
benzamido group, and thus the increased
mortality described in the University
Group Diabetes Program could not be at-
tributed to interaction between this moi-
ety and SUR2A solely.
In the UKPDS, combination therapy
of metformin and sulfonylureas was asso-
ciated with an increased risk of diabetes-
relateddeath(hazardratio[HR]1.96)and
fatal MI (HR 1.79) (2). In a more recent
retrospective population-based cohort
study, sulfonylurea therapy was associ-
ated with increased cardiovascular mor-
tality with a 2.1 HR for older sulfonylurea
agents (chlorpropamide or tolbutamide)
and1.3fornewerdrugssuchasglyburide
(17). Furthermore, in the Action to Con-
trol Cardiovascular Risk in Diabetes (AC-
CORD) study, intensive glucose control
was associated with a signiﬁcant increase
in hypoglycemic events and cardiovascu-
lar mortality (18). Although subanalysis
of the contribution of different glucose-
loweringagentstotheincreasedmortality
in this study is not available, the associa-
tion of higher rates of hypoglycemia and
increased cardiovascular mortality is in-
Oral hypoglycemic agents and cardiovascular disease
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cern regarding adverse cardiovascular
effects that sulfonylureas may exert, con-
sidering the frequent hypoglycemic
events associated with this class of drugs.
Metformin
Metformin lowers plasma glucose levels
by suppressing hepatic gluconeogenesis
and glycogenolysis, while increasing pe-
ripheral sensitivity to insulin. Its beneﬁ-
cial effects on glucose metabolism are not
accompanied by weight gain, a clear ad-
vantage over other commonly used
OHAs. Multiple randomized controlled
trials examined the effect of metformin
therapy on blood pressure in diabetic pa-
tients. The results of these studies were
inconsistent, ranging from no effect to a
small positive effect on diastolic blood
pressure (13,19).
The effect of metformin on lipid pro-
ﬁle is favorable. It signiﬁcantly reduces
plasma triglyceride levels, a result related
toimprovedglucoselevels(9).Modestre-
duction in LDL levels was demonstrated
with metformin therapy. However, anal-
ysis of 29 trials failed to demonstrate sig-
niﬁcant elevation in HDL levels with
metformin (19). Studies also failed to
demonstrate a clear beneﬁt of metformin
on microalbuminuria in diabetic patients
(14).
The effect of metformin on systemic
inﬂammation that accompanies athero-
sclerosis has been examined. Although it
isassociatedwithreducedoxidativestress
and lower C-reactive protein levels in
treatedsubjects,metformintherapyledto
increased plasma levels of TNF- in lean
subjects. Noteworthy, the TNF- levels
did not change in obese subjects treated
with metformin (20). Metformin also ex-
erts a positive inﬂuence on endothelial
dysfunction and coagulation abnormali-
ties related to diabetes.
The effect of metformin on clinical
surrogate markers of cardiovascular dis-
ease was addressed by Matsumoto et al.
(21). In this study, metformin therapy
was associated with attenuated progres-
sion of carotid intima-media thickness
(IMT). However, the results of this study
are questionable because of its open-label
design, and the limited number of sub-
jects included. Moreover, the validity of
the association between IMT progression
and future cardiovascular events was not
completelyconﬁrmed.InthestudybySa-
lonen and Salonen (22), the increase in
cardiovascular events was not signiﬁ-
cantly related to carotid IMT. In another
study by Bots et al., the association be-
tween IMT and cardiovascular events did
not reach statistical signiﬁcance after
other risk factor adjustment (23). This
was in contrast to the incidence of stroke
that was clearly related to IMT.
The UKPDS trial was the ﬁrst to dem-
onstrate improved clinical outcome with
metformin in diabetic subjects. Met-
formin monotherapy in conjunction with
diet improved cardiovascular outcome
with a 39% reduction in MI rates, com-
pared with conventional therapy alone in
overweight patients (2). Moreover, the
UKPDS post-trial monitoring study dem-
onstrated 33% risk reduction in the met-
formin-treated patients (7). Increased
insulin sensitivity and enhanced ﬁbrino-
lytic activity due to reduction in plasmin-
ogen activator inhibitor 1 levels are
possibleexplanationsforthefavorablere-
sult (24).
Nevertheless, in a combined analysis
of the data from the same trial and a sup-
plementary trial where metformin was
given in combination with sulfonylureas,
the effect of metformin on cardiovascular
outcomes was not substantiated, due to
increased cardiovascular mortality in the
combination group (HR 1.96) (2).
In a retrospective population-based
cohort study, metformin was associated
with a slight decrease in cardiovascular
mortality. However, this change did not
reach statistical signiﬁcance (17). Given
together, accumulating data indicate a
possible favorable effect of metformin
therapy on cardiovascular outcome (25);
however, additional data are still needed
to prove that metformin signiﬁcantly re-
duces cardiovascular events and cardio-
vascular mortality in diabetic patients.
Thiazolidinediones
Thiazolidinediones (TZDs) activate the
transcription factor peroxisome prolifera-
tor–activated receptor (PPAR)-. Upon
activation, PPAR- modulates the expres-
sion of genes that are involved in glucose
and lipid metabolism leading to de-
creased insulin resistance and improved
-cell function. The TZDs are associated
with weight gain, increase in subcutane-
ous fat, and a possible decrease in visceral
adipose tissue (26). The two most fre-
quentlyusedTZDs,rosiglitazoneandpio-
glitazone,havedifferentialeffectsonlipid
proﬁle. Pioglitazone lowers triglycerides
and increases HDL levels with a neutral
effect on LDL. Rosiglitazone increases
HDL and LDL, leaving the triglyceride
levels unchanged (26,27). It is notewor-
thy that these results were described in
patients who were not on lipid-lowering
agents. In a study of patients who had
already been treated with statins, switch-
ing from rosiglitazone to pioglitazone re-
sulted in reduced triglycerides and LDL
levels, rendering HDL unchanged (28).
Thiazolidinedionesexertfavorableef-
fects on hypertension by lowering both
systolic and diastolic blood pressure
when compared with placebo and with
other OHAs (29). The blood pressure–
loweringpropertiesofTZDsareatleastin
partrelatedtoimprovedendothelialfunc-
tion and restoration of vascular reactivity.
As a monotherapy and in combina-
tion, TZDs reduce microalbuminuria,
suggesting renoprotective properties and
improved endothelial function (14).
In general, TZDs demonstrate anti-
inﬂammatory features, with reduction in
C-reactiveproteinandTNF-levels(27),
and increased adiponectin plasma con-
centrations in treated patients (30). The
TZDs also seem to have beneﬁcial ef-
fects on plaque stability and ﬁbrinolytic
activity.
Several studies examined the effect of
TZDsonclinicalsurrogatemarkersofcar-
diovascular complications. Pioglitazone
therapy was associated with reduced ca-
rotidIMTcomparedwithglimepiride,in-
dependently from glycemic control (31).
However, cardiovascular outcome results
cannot be extrapolated from these data
because of the lack of a solid association
between IMT and cardiovascular out-
come. Likewise, the reduction in the
rate of stent restenosis with rosiglita-
zone (32) and pioglitazone (33) as-
sessed by coronary angiography cannot
be conclusively interpreted as a reduc-
tion in cardiovascular events. The inter-
action between these drugs and the
tissue repair reaction at the site of stent
placement and its relevance to cardiac
events needs further investigation.
In the Comparison of Pioglitazone vs.
Glimepiride on Progression of Coronary
Atherosclerosis in Patients With Type 2
Diabetes (PERISCOPE) study, coronary
atheroma volume was assessed by intra-
vascular coronary ultrasound. In this
study, pioglitazone was associated with
0.16% decrease in percent atheroma vol-
ume, compared with glimepiride, where
percent atheroma volume was increased
by 0.73% (34). Although promising,
these ﬁndings could not be considered
clear favorable clinical outcomes.
Data from recent years induced con-
cern regarding the cardiovascular safety
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Wolski (35) demonstrated an increased
incidence of MI in patients treated with
rosiglitazone. Although not statistically
signiﬁcant, a trend of increased cardio-
vascular death (P  0.06) is a cause for
concern. In a subsequent meta-analysis
by Singh et al. (36), the data on in-
creased MI was conﬁrmed. However,
the data on cardiovascular mortality
was not reproduced.
The effect of pioglitazone on clinical
outcome was examined in the PROspec-
tive pioglitAzone Clinical Trial In macro-
Vascular Events (PROactive) study (37).
In this study, pioglitazone was examined
for secondary prevention in patients with
established macrovascular disease. Al-
though post hoc analysis of the subgroup
with previous MI demonstrated signiﬁ-
cant risk reduction of recurrent MI, or
acute coronary syndrome (38), no signif-
icant reduction in cardiovascular events
wasdemonstratedintheoriginalstudy.In
a recent meta-analysis of randomized tri-
als, pioglitazone was associated with re-
duction in all-cause mortality but had no
effect on nonfatal coronary events (39).
-Glucosidase inhibitors
By inhibiting intestinal glucosidases,
-glucosidase inhibitors result in delayed
carbohydrateabsorptionandﬂatteningof
the postprandial glucose curve. Despite
consistent results on improved glycemia
with these agents, the majority of studies
demonstrated no effect on lipid proﬁle,
blood pressure, or microalbuminuria (9).
In the STOP-NIDDM study, acarbose
therapy was alleged to be associated with
decreased rates of MI (40). However,
these ﬁndings were profoundly ques-
tioned because of study design and
mainly the very small number of subjects
included. Thus, large and well-designed
trials examining clinical end points with
-glucosidase inhibitors are lacking.
Finally,thereisnoclearevidencethat
good glycemic control improves macro-
vascular complication risk. Despite the
large amount of data on the effects of
OHAs on different metabolic and clinical
surrogatemarkers,theevidenceforfavor-
able cardiovascular clinical outcome is
relatively sparse. Nevertheless, there are
serious safety concerns for some OHAs,
such as sulfonylureas and TZDs. Addi-
tional studies are needed to further char-
acterize the beneﬁts and impairments of
the commonly used OHAs.
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